Acer Therapeutics Inc. Contracts & Agreements
168 Contracts & Agreements
- Business Finance (79 contracts)
- Business Operations (16)
- Human Resources (30)
- Intellectual Property (9)
- Mergers & Acquisitions (2)
- Real Estate (7)
- Uncategorized (25)
- Agreement and Plan of Merger dated as of August 30, 2023 by and among Zevra Therapeutics, Inc., Aspen Z Merger Sub, Inc., and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Bridge Loan Agreement dated as of August 30, 2023 by and between Zevra Therapeutics, Inc. and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Security Agreement dated as of August 30, 2023 by and between Zevra Therapeutics, Inc. and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Exclusive License Agreement dated as of August 28, 2023 by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AB (Filed With SEC on August 31, 2023)
- Amendment No. 1 to Unsecured Promissory Note dated as of August 30, 2023 by and between Acer Therapeutics Inc. and Christopher Schelling (Filed With SEC on August 31, 2023)
- Termination Agreement dated as of August 28, 2023 by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AB (Filed With SEC on August 31, 2023)
- Warrant issued on June 16, 2023, by the Company to SWK Funding LLC (Filed With SEC on August 14, 2023)
- Unsecured Promissory Note, dated as of June 22, 2023, between Acer Therapeutics Inc. and Christopher Schelling (Filed With SEC on June 26, 2023)
- Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on March 22, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on March 22, 2023)
- Form of Securities Purchase Agreement, dated as of March 21, 2023, between Acer Therapeutics Inc. and the Purchaser (Filed With SEC on March 22, 2023)
- Second Amendment to Credit Agreement dated January 30, 2023, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole... (Filed With SEC on January 31, 2023)
- Warrant issued on January 30, 2023, by the Company to SWK Funding LLC pursuant to the Second Amendment to Credit Agreement dated January 30, 2023, among Acer Therapeutics Inc.,... (Filed With SEC on January 31, 2023)
- Amendment Agreement dated January 30, 2023, with respect to Secured Convertible Note Purchase Agreement between Acer Therapeutics Inc., MAM Aardvark, LLC and Marathon Healthcare... (Filed With SEC on January 31, 2023)
- Termination Agreement dated as of January 30, 2023 among Acer Therapeutics Inc., the Lenders party thereto and MAM Aardvark, LLC, not individually, but solely in its capacity as... (Filed With SEC on January 31, 2023)
- Extension Agreement, dated as of December 30, 2022, among Acer Therapeutics Inc., MAM Aardvark, LLC as administrative and collateral agent for the lenders, and the lenders party... (Filed With SEC on January 3, 2023)
- Securities Purchase Agreement, dated November 29, 2022, by and between Acer Therapeutics Inc. and the investors listed on Schedule I thereto (Filed With SEC on November 30, 2022)
- Amendment to Credit Agreement dated August 19, 2022, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole... (Filed With SEC on August 23, 2022)
- Warrant issued on August 19, 2022, by the Company to SWK Funding LLC pursuant to the Amendment to Credit Agreement dated August 19, 2022, among Acer Therapeutics Inc., the lenders... (Filed With SEC on August 23, 2022)
- Employment Agreement between Acer Therapeutics Inc. and Tanya Hayden dated June 19, 2022 (Filed With SEC on June 21, 2022)
- Credit Agreement dated March 4, 2022, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole bookrunner (Filed With SEC on March 7, 2022)
- Guarantee and Collateral Agreement dated March 4, 2022, among Acer Therapeutics Inc. and SWK Funding LLC, as agent (Filed With SEC on March 7, 2022)
- Warrant issued on March 4, 2022, by the Company to SWK Funding LLC pursuant to the Credit Agreement dated March 4, 2022, among Acer Therapeutics Inc., the lenders party thereto... (Filed With SEC on March 7, 2022)
- Secured Convertible Note Purchase Agreement dated March 4, 2022, between Acer Therapeutics Inc., MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P (Filed With SEC on March 7, 2022)
- Form of Secured Convertible Note issuable by Acer Therapeutics Inc. to MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. pursuant to the Secured Convertible Note... (Filed With SEC on March 7, 2022)
- Credit Agreement dated March 4, 2022, among Acer Therapeutics Inc., the lenders party thereto and MAM Aardvark, LLC, as the agent, sole lead arranger and sole bookrunner (Filed With SEC on March 7, 2022)
- Form of Guarantee and Collateral Agreement to be dated the Term Loan Funding Date among Acer Therapeutics Inc. and MAM Aardvark, LLC, as agent (Filed With SEC on March 7, 2022)
- Synthetic Royalty Agreement dated March 4, 2022, between Acer Therapeutics Inc., MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P (Filed With SEC on March 7, 2022)
- Employment Agreement, dated January 14, 2022, by and between Acer Therapeutics Inc. and Bernie Paul (Filed With SEC on March 2, 2022)
- Lease Agreement, dated October 15, 2021, by and between Acer Therapeutics Inc. and Commonwealth Development LLC, as trustee of the Gateway Realty Trust (Filed With SEC on March 2, 2022)
- Second Amendment, dated November 17, 2021, by and between Acer Therapeutics Inc. and Eastern Western Corp (Filed With SEC on March 2, 2022)
- Acer Therapeutics Inc. 2018 Stock Incentive Plan, as amended and restated (Filed With SEC on February 22, 2022)
- Employment Agreement, dated February 21, 2022, between Acer Therapeutics Inc. and Adrian W. Quartel (Filed With SEC on February 22, 2022)
- Notice of Stock Option Grant (Inducement Award) and Stock Option Agreement (Inducement Award), dated February 21, 2022, between Acer Therapeutics Inc. and Adrian W. Quartel for... (Filed With SEC on February 22, 2022)
- Waiver and Agreement, dated October 6, 2021, by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AG (Filed With SEC on October 8, 2021)
- Agreement of Access and Use of Clinical Trial Data, dated as of August 3, 2016, by and between LAssistance Publique Hpitaux de Paris and Acer Therapeutics Inc (Filed With SEC on August 10, 2021)
- First Amendment, dated April 23, 2019, by and between Acer Therapeutics Inc. and Eastern Western Corp (Filed With SEC on August 10, 2021)
- Exclusive License Agreement, dated as of April 4, 2014, by and between Acer Therapeutics Inc. and Baylor College of Medicine (Filed With SEC on May 17, 2021)
- Collaboration and License Agreement, dated March 19, 2021, by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AG (Filed With SEC on March 22, 2021)
- Form of Notice of Stock Option Grant and Stock Option Agreement for option awards to be made under the 2018 Stock Incentive Plan (Filed With SEC on March 1, 2021)
- Employment Agreement, dated February 1, 2021, by and between Acer Therapeutics Inc. and Jefferson E. Davis (Filed With SEC on March 1, 2021)
- Option Agreement, dated January 25, 2021, by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AG (Filed With SEC on January 25, 2021)
- Promissory Note, dated January 25, 2021, issued by Acer Therapeutics Inc. in favor of Relief Therapeutics Holding AG (Filed With SEC on January 25, 2021)
- Security Agreement, dated January 25, 2021, by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AG (Filed With SEC on January 25, 2021)
- Exclusive License Agreement, dated as of December 21, 2018, by and between Acer Therapeutics Inc. and Sanofi (Filed With SEC on August 13, 2020)
- Securities Purchase Agreement, dated July 24, 2020, by and between Acer Therapeutics Inc. and the investors listed on Schedule I thereto (Filed With SEC on July 27, 2020)
- Research Collaboration Agreement, dated March 26, 2020, by and between Acer Therapeutics Inc. and the National Center for Advancing Translational Sciences (Filed With SEC on June 1, 2020)
- Purchase Agreement, dated as of April 30, 2020 by and between Acer Therapeutics Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 30, 2020)
- Registration Rights Agreement, dated as of April 30, 2020 by and between Acer Therapeutics Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 30, 2020)
- Description of the Companys capital stock registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 18, 2020)
- Amended and Restated Sales Agreement, dated March 18, 2020 by and among Acer Therapeutics Inc., Roth Capital Partners, LLC, and JonesTrading Institutional Services LLC (Filed With SEC on March 18, 2020)
- Employment agreement, dated September 18, 2019, by and between Acer Therapeutics Inc. and John Klopp (Filed With SEC on November 13, 2019)
- Employment agreement, dated September 18, 2019, by and between Acer Therapeutics Inc. and Matthew T. Seibt (Filed With SEC on November 13, 2019)
- Lease Agreement, dated March 5, 2019, by and between Acer Therapeutics Inc. and Commonwealth Development LLC, as a trustee of the Gateway Realty Trust (Filed With SEC on August 13, 2019)
- Form of Notice of Restricted Stock Award for awards under the 2018 Stock Incentive Plan (Filed With SEC on March 7, 2019)
- Employment Agreement, dated December 4, 2018, by and between Acer Therapeutics Inc. and Salma Jutt-Eghbali (Filed With SEC on March 7, 2019)
- License Agreement for Development and Exploitation, dated as of September 19, 2018, by and between Acer Therapeutics Inc. and Assistance Publique Hpitaux de Paris (Filed With SEC on November 9, 2018)
- Sales Agreement, dated November 9, 2018, by and between Acer Therapeutics Inc. and Roth Capital Partners, LLC (Filed With SEC on November 9, 2018)
- Underwriting Agreement, dated August 1, 2018, by and among Acer Therapeutics Inc. and William Blair & Company, L.L.C. and Raymond James & Associates, Inc., as representatives of... (Filed With SEC on August 1, 2018)
- Plan of Conversion, dated May 15, 2018 (Filed With SEC on May 15, 2018)
- Specimen common stock certificate (Filed With SEC on May 15, 2018)
- Form of Notice of Stock Option Grant and Stock Option Agreement for option awards to be made under the 2018 Stock Incentive Plan (Filed With SEC on May 15, 2018)
- Employment Agreement, dated April 20, 2018, by and between Acer Therapeutics Inc. and Donald Joseph (Filed With SEC on May 14, 2018)
- Lease Agreement, dated March 6, 2018, by and between Acer Therapeutics Inc. and Commonwealth Development LLC, as trustee of the Gateway Realty Trust (Filed With SEC on May 14, 2018)
- Triple Net Lease, dated April 1, 2018, by and between Acer Therapeutics Inc. and Eastern Western Corp (Filed With SEC on May 14, 2018)
- Sublease Agreement, dated as of October 16, 2017, by and between Acer Therapeutics Inc. and Bradley A. MacDonald (Filed With SEC on March 7, 2018)
- Employment Agreement, dated February 22, 2018, by and between Acer Therapeutics Inc. and Chris Schelling (Filed With SEC on February 27, 2018)
- Employment Agreement, dated February 22, 2018, by and between Acer Therapeutics Inc. and William Andrews (Filed With SEC on February 27, 2018)
- Employment Agreement, dated February 22, 2018, by and between Acer Therapeutics Inc. and Harry Palmin (Filed With SEC on February 27, 2018)
- Underwriting Agreement, dated December 12, 2017, by and between Acer Therapeutics Inc. and William Blair & Company, L.L.C., as Representative of the several underwriters (Filed With SEC on December 12, 2017)
- Specimen common stock certificate (Filed With SEC on November 13, 2017)
- Acer Therapeutics Inc. 2013 Stock Incentive Plan (Filed With SEC on September 20, 2017)
- SUBSCRIPTION AGREEMENT (Filed With SEC on July 19, 2017)
- AGREEMENT OF ACCESS AND USE OF CLINICAL TRIAL DATA (Agreement) VAL 2016/2015-419 (Filed With SEC on July 19, 2017)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on July 19, 2017)
- FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on July 19, 2017)
- SECOND AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on July 19, 2017)
- THIRD AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on July 19, 2017)
- Acer Therapeutics Inc. Consulting Agreement (Filed With SEC on July 19, 2017)
- Acer Therapeutics Inc. First Amendment to Consulting Agreement (Filed With SEC on July 19, 2017)
- BUSINESS ADVISORY AGREEMENT Prepared For September 2015 ACER THERAPEUTICS INC. BUSINESS ADVISORY AGREEMENT (Filed With SEC on July 19, 2017)
- AMENDMENT TO BUSINESS ADVISORY AGREEMENT (Filed With SEC on July 19, 2017)
- SEVERANCE AGREEMENT (Filed With SEC on July 19, 2017)
- SEVERANCE AGREEMENT (Filed With SEC on July 19, 2017)
- Acer Therapeutics Inc. |222 Third Street, Suite 2240 | Cambridge, MA 02142 | www.acertx.com (Filed With SEC on July 19, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on July 19, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on July 19, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on July 19, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on July 19, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on July 19, 2017)
- OPEXA THERAPEUTICS, INC. AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN AMENDMENT NO. 1 (Filed With SEC on July 19, 2017)
- AGREEMENT AND PLAN OF MERGER AND REORGANIZATION Among OPEXATHERAPEUTICS, INC. OPEXA MERGER SUB, INC., and ACER THERAPEUTICS INC. Dated as of June 30, 2017 Table of Contents (Filed With SEC on July 3, 2017)
- SUPPORT AGREEMENT (Filed With SEC on July 3, 2017)
- SUPPORT AGREEMENT (Filed With SEC on July 3, 2017)
- Assignment and Assumption of Lease, dated February 1, 2017, by and between Opexa Therapeutics, Inc. and KBI Biopharma, Inc (Filed With SEC on February 1, 2017)
- OPEXA THERAPEUTICS, INC. DOCSĀ® ATM financing facility Shares of Common Stock, $0.01 par value SALES AGREEMENT March 25, 2016 (Filed With SEC on March 25, 2016)
- AMENDMENT TO STOCK PURCHASE AGREEMENT (Filed With SEC on March 15, 2016)
- OPEXA THERAPEUTICS, INC. 2635 N. Crescent Ridge Drive The Woodlands, TX 77381 March 2, 2010 (Filed With SEC on March 15, 2016)
- N-_September 1, 2015 (Filed With SEC on September 1, 2015)
- STOCK PURCHASE AGREEMENT (Filed With SEC on September 1, 2015)
- Warrant Agreement, dated February 25, 2015, by and between Opexa Therapeutics, Inc. and Continental Stock Transfer & Trust Company (Filed With SEC on May 12, 2015)
- Subscription Agent Agreement, dated February 25, 2015, by and between Opexa Therapeutics, Inc. and Continental Stock Transfer & Trust Company (Filed With SEC on May 12, 2015)
- First Amendment to Lease Agreement, dated May 11, 2015, by and between Opexa Therapeutics, Inc. and Dirk D. Laukien (Filed With SEC on May 12, 2015)
- Form of restricted stock agreement for awards to be made under the Opexa Therapeutics, Inc. 2010 Stock Incentive Plan (Filed With SEC on May 12, 2015)
- First Amendment of Option and License Agreement (Filed With SEC on March 9, 2015)
- FORM OF OPEXATHERAPEUTICS, INC. DEALER-MANAGER AGREEMENT , 2015 (Filed With SEC on February 24, 2015)
- FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE (Filed With SEC on February 24, 2015)
- SUBSCRIPTION AGENT AGREEMENT [ ], 2015 (Filed With SEC on February 24, 2015)
- FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE (Filed With SEC on February 24, 2015)
- SUBSCRIPTION AGENT AGREEMENT [ ], 2015 (Filed With SEC on February 24, 2015)
- [Form of Warrant Certificate] [FACE] (Filed With SEC on January 28, 2015)
- OPEXA THERAPEUTICS, INC. and CONTINENTAL STOCKTRANSFER & TRUST COMPANY WARRANT AGREEMENT Dated as of [ ], 2015 (Filed With SEC on January 28, 2015)
- OPEXA THERAPEUTICS, INC. AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on August 14, 2014)
- FIRST AMENDMENT TO SALES AGREEMENT (Filed With SEC on March 5, 2014)
- UNDERWRITING AGREEMENT between OPEXATHERAPEUTICS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters OPEXA THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on December 18, 2013)
- OMNIBUS AMENDMENT TO ALL OUTSTANDING 12% CONVERTIBLE SECURED PROMISSORY NOTES OF OPEXA THERAPEUTICS, INC. AND ASSOCIATED REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 25, 2013)
- UNDERWRITING AGREEMENT between OPEXA THERAPEUTICS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters OPEXA THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on July 22, 2013)
- OPEXA THERAPEUTICS, INC. 2635 Technology Forest Blvd. The Woodlands, TX 77381 March 12, 2013 (Filed With SEC on April 1, 2013)
- TERMINATION AGREEMENT, WAIVER, AND RELEASE (Filed With SEC on April 1, 2013)
- CONSULTING AGREEMENT (Filed With SEC on April 1, 2013)
- WAIVER AND OMNIBUS AMENDMENT (Filed With SEC on March 29, 2013)
- PLACEMENT AGENCY AGREEMENT February 7, 2013 (Filed With SEC on February 7, 2013)
- COMMON STOCK PURCHASE WARRANT OPEXA THERAPEUTICS, INC. Warrant Shares: _______Initial Exercise Date: February __, 2013 (Filed With SEC on February 7, 2013)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on February 7, 2013)
- K-[]January 29, 2013 OPEXA THERAPEUTICS, INC. SERIES K WARRANT TO PURCHASE SHARES (Filed With SEC on January 30, 2013)
- J-___January 23, 2013 OPEXA THERAPEUTICS, INC. SERIES J WARRANT TO PURCHASE SHARES OF COMMON STOCK, PAR VALUE $0.01 PER SHARE (Filed With SEC on January 23, 2013)
- OPEXA THERAPEUTICS, INC. 12% CONVERTIBLE PROMISSORY NOTE $__________January 23, 2013 (Filed With SEC on January 23, 2013)
- PURCHASE AGREEMENT (Filed With SEC on November 5, 2012)
- PURCHASE AGREEMENT (Filed With SEC on November 5, 2012)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 5, 2012)
- OPEXA THERAPEUTICS, INC. DOCS ATM financing facility Shares of Common Stock, $0.01 par value SALES AGREEMENT September 6, 2012 (Filed With SEC on September 7, 2012)
- No.I-_______July 25, 2012 (Filed With SEC on July 26, 2012)
- CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF OPEXA THERAPEUTICS, INC. ___________________ Pursuant to Sections... (Filed With SEC on July 26, 2012)
- NOTE PURCHASE AGREEMENT (Filed With SEC on July 26, 2012)
- OPEXA THERAPEUTICS, INC. 12% CONVERTIBLE SECURED PROMISSORY NOTE (Filed With SEC on July 26, 2012)
- SECURITY AGREEMENT (Filed With SEC on July 26, 2012)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 26, 2012)
- ASSIGNMENT AGREEMENT AND GENERAL RELEASE (Filed With SEC on November 4, 2011)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on June 30, 2011)
- 4,146,500 Units par value $0.01 OPEXA THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on February 8, 2011)
- OPEXA THERAPEUTICS, INC. FORM OFWARRANT TO PURCHASE COMMON STOCK (Filed With SEC on February 8, 2011)
- OPEXA THERAPEUTICS, INC. 2010 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on October 22, 2010)
- CONTINUOUS OFFERING PROGRAM AGREEMENT May 14, 2010 (Filed With SEC on May 17, 2010)
- EXHIBIT 4.1 FIRST AMENDMENT TO PROMISSORY NOTE AND SECURITY AGREEMENT (Filed With SEC on May 13, 2010)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on April 27, 2010)
- OPEXA THERAPEUTICS, INC. 2635 N. Crescent Ridge Drive The Woodlands, TX 77381 November 16, 2009 (Filed With SEC on March 5, 2010)
- CERTIFICATE OF AMENDMENTS TO THE (Filed With SEC on March 5, 2010)
- Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 (Filed With SEC on December 10, 2009)
- COMMON STOCK PURCHASE WARRANT OPEXA THERAPEUTICS,INC. (Filed With SEC on December 10, 2009)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 10, 2009)
- Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED WITH [*]. AN UNREDACTED VERSION OF THIS... (Filed With SEC on August 7, 2009)
- UNIT PURCHASE AGREEMENT (Filed With SEC on April 16, 2009)
- OPEXA THERAPEUTICS, INC. 10% CONVERTIBLE PROMISSORY NOTE (Filed With SEC on April 16, 2009)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 16, 2009)
- OPEXA THERAPEUTICS, INC. SERIES G WARRANT TO PURCHASE ____ SHARES OF COMMON STOCK, PAR VALUE $0.50 PER SHARE (Filed With SEC on April 16, 2009)
- SECURITY AGREEMENT (Filed With SEC on April 16, 2009)
- EMPLOYMENT AGREEMENT (Filed With SEC on April 16, 2009)
- UNIT PURCHASE AGREEMENT (Filed With SEC on August 13, 2008)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 13, 2008)
- OPEXA THERAPEUTICS, INC. SERIES F WARRANT TO PURCHASE ________ SHARES OF COMMON STOCK, PAR VALUE $0.50 PER SHARE (Filed With SEC on August 13, 2008)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 18, 2008)
- AMENDMENT TO EMPLOYMENTAGREEMENT (Filed With SEC on May 13, 2008)
- EMPLOYMENTAGREEMENT (Filed With SEC on May 13, 2008)
- EMPLOYMENTAGREEMENT (Filed With SEC on May 13, 2008)
- EMPLOYMENTAGREEMENT (Filed With SEC on May 13, 2008)
- 3,500,000 Shares and 3,500,000 Warrants OPEXA THERAPEUTICS, INC. Common Stock and Common Stock Purchase Warrants UNDERWRITING AGREEMENT February 13, 2008 (Filed With SEC on February 14, 2008)
- FORM OF (Filed With SEC on February 14, 2008)
- FORM OF UNDERWRITERS WARRANT TO ACQUIRE WARRANTS AGREEMENT (Filed With SEC on February 14, 2008)